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A B S T R A C T
Background and Purpose of the study: Axillary lymph node status at the time of diagnosis remains one of the
most important prognostic factors in women with breast cancer. Sentinel lymph node biopsy (SLNB) proved
to be a reliable method for the evaluation of axillary nodal status in early-stage invasive breast cancer. The
prognostic value and potential therapeutic consequences of SLN micrometastases remains a matter of great
debate.
Patients and Methods: From January 1998 to March 2011, 1,976 consecutive patients with non-metastatic
invasive breast cancer underwent surgical treatment; 1,080 of them (54.6%) underwent SLNB. We
collected data regarding demography, preoperative lymphoscintigraphy, type of surgery, histopathologic and
immunohistochemical features and adjuvant treatment.
Main ﬁndings: A mean number of 2.1±1.4 (range 1–13) SLN per patient were collected, a total of
2,294 nodes. SLNs were macrometastatic in 16.7% of patients and micrometastatic in 3.3%. Among the
patients with positive SLN 93.6% underwent complete ALND. The overall survival (OS) and disease-free
survival (DFS) of 72 patients with micrometastases in SLN at 60 months was 100%, similar to patients
with negative SLN (98.7%), quite different from the DFS of N1–N3 patients (85.8%). Statistically signiﬁcant
differences in OS and DFS were observed between patients with N1mi and the group with N1–N3 sentinel
node (p < 0.001 and p=0.04) and also between patients with negative SLN and those with macrometastatic
SLN (p < 0.001 for both).
Conclusion: SLN micrometastases could represents an epiphenomenon of peritumoral lymphovascular
invasion which impacts independently on the survival of patients with invasive breast cancer.
© 2013 Surgical Associates Ltd. Published by Elsevier Ltd. All rights reserved.
1. Introduction
Axillary lymph node status at the time of diagnosis remains one
of the most important prognostic indicators for women with breast
cancer. 1 The presence of lymphogenic metastases and number of
lymph nodes involved signiﬁcantly contribute to adjuvant systemic
treatment decision; in fact they are associated with an increased
probability of recurrence and mortality. 2,3
The goal of axillary lymph node dissection is to provide accurate
staging information and local control of disease. However, the
procedure hasmany potential complications, including lymphedema,
persistent seroma, shoulder disfunction and paresthesias. 4
Nowadays, sentinel lymph node biopsy (SLNB) provides informa-
tion on the axillary node status with lower morbidity than complete
axillary lymph node dissection (ALND). Therefore, according to the
results of several international randomized trials SLNB is considered
the standard of care for patients with early breast cancer and negative
axillary nodes. 5,6
The complexity of breast tumor biology has changed cancer treat-
ments, consequently the choice of administering systemic therapy is
inﬂuenced by a variety of clinical and pathology-related factors, with
lymph node tumor status inﬂuencing but not necessarily dictating
the use of chemotherapy. 7 These evolving concepts have called into
question the need for ALND, especially for limited sentinel lymph
node involvement.
Published data suggest that the absence of metastatic tumor
cells in the sentinel lymph node accurately predicts the absence of
metastases in the remaining axillary nodes in 95–100% of cases. 8–10
Actually, SLNB may be more sensitive to detect metastases than
axillary node dissection. 4 Compared with analysis with hematoxylin
and eosin (H&E) only in axillary lymph node dissection specimens,
the use of step sectioning and immunohistochemistry in the sentinel
lymph node results in a more accurate histopathologic examination
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and is associated with a higher detection rate of small metastases
(micrometastases and isolated tumor cells). 11,12 In the 7th edition
of the AJCC staging system the concept of “micrometastases” (N1mi)
has been introduced in the ofﬁcial staging criteria: micrometastase
is deﬁned as a metastases measuring from 0.2mm to not more
than 2.0mm. 13
However, the prognostic signiﬁcance of micrometastases in the
sentinel node is currently unclear and creates a new dilemma in the
clinicalmanagement of patientswith breast cancer. 14 In this studywe
examine the overall survival and disease free survival of a large cohort
of patients in order to assess the prognostic meaning of sentinel node
micrometastases.
2. Patients and methods
From January 1998 to March 2011, 1,991 consecutive patients with
invasive breast cancer underwent surgical treatment at theDivision of
General Surgery of Ospedale di Circolo, University of Insubria Varese.
For the present study, 15 patients with distant metastases at the
time of diagnosis were excluded, hence the sample consisted of
1,976 patients, whose mean age at diagnosis was 61.1±12.4 years;
1,080 of them (54.6%) underwent sentinel lymph node biopsy. The
other patients did not undergo sentinel node biopsy either because
they were treated before the introduction of the sentinel lymph
node biopsy technique into routine clinical practice (2001) or due to
evidence of metastatic axillary nodes.
We retrospectively collected data regarding demography, pre-
operative lymphoscintigraphy, type of surgery, histopathologic and
immunohistochemical features and adjuvant treatment.
Pathologic assessment included evaluation of the size, grade,
histological type, peritumoral vascular invasion of the primary tumor
and lymph node status.
Data regarding tumor expression of estrogen and progesterone
receptors, Ki-67 antigen, HER-2 and p53 over-expression were also
collected.
The nodal statuswas determined according to the 7th edition of the
AJCC cancer staging manual. 13 If no regional lymph node metastasis
was detected, the tumor was classiﬁed as pN0.
In case ofmicrometastases (larger than 0.2mmbut none larger than
2mm in greatest dimension) the tumor was classiﬁed as pN1mi. If
nodal metastases larger than 2mm were diagnosed, the tumor was
classiﬁed as pN1. 13
2.1. Lymphatic mapping and operative technique
Sentinel node mapping was performed using a radiolabelled colloid.
The day before surgery 99mTc- labelled nanocolloid (Nanocoll) was
injected intradermally above the tumor site. Lymphoscintigraphywas
performed preoperatively to identify lymphatic ﬂow to axillary lymph
nodes, hot spots were marked on the skin.
SLN was intraoperatively identiﬁed by use of a gamma probe
(Neoprobe); all hot lymph nodeswere excised and labelled separately
as SLN, until all hot lymph nodes had been removed, and the
background count of the axilla was <10% of the hottest lymph node. 14
If no SLNs were found, a complete ALND was performed.
2.2. Surgical treatment
All patients received adequate local treatment (breast-conserving
surgery or total mastectomy) plus SLNB or ALND.
2.3. Pathological examination of sentinel nodes
Intraoperative frozen section analysis of the axillary SLN was
routinely conducted in order to perform axillary dissection during the
same operative procedure in case of lymphatic metastases.
Lymph nodes >5mm in diameterwere bisected, nodes5mmwere
not bisected but totally submitted for frozen section analysis; the
sections were cut at 50–200mm intervals and they were examined
with H&E. In addition, the sentinel nodes were ﬁxed in formaline and
embedded in parafﬁn for deﬁnitive histopathologic analysis. During
the deﬁnitive histopathologic analysis the sections were stained
with both H&E and immunohistochemically with antibodies against
keratin. 14,15
2.4. Adjuvant therapy
When breast-conservative surgery was performed, patients received
adjuvant radiotherapy with 50Gy over 5 weeks with a boost of
10Gy to the tumor site, marked with clips during surgery in patients
without contraindications for radiotherapy.
Moreover, adjuvant therapy consisted of hormone treatment
(tamoxifen or aromatase inhibitors), and/or chemotherapy according
to established prognostic factors (age, comorbidities, axillary lymph
node status and features of primary tumor). 16,17
On the basis of the St. Gallen Consensus recommendations, 17,18
patients with SN micrometastases were considered SN negative
and adjuvant therapy was administered only according to the
characteristics of the primary tumor.
2.5. Follow up
After surgery, patients were observed every 4 months in the ﬁrst
3 years, every 6months in the next 2 years, and once a year thereafter;
mammography and breast ultrasound were performed annually.
Registry ofﬁces were actively contacted for additional information,
especially for the cause of death, when patients were lost to
follow up.
Follow up started at the time of the operation. As per December
2011, 63 patients (3.2%)were lost to follow up; in the survival analyses
these were “censored” at the time of last contact.
For all patients, the median follow-up was 53.4 months (range
1–160 months) and for the survivors the median follow-up was
55.3 months (range 1–160 months).
2.6. Statistical analysis
The primary end-points were overall and disease-free survival of
our group of patients in order to calculate the survival impact of
SN micrometastases.
Disease-free survival (DFS) was deﬁned as the lenght of time from
the date of surgery to any relapse; overall survival (OS) was deﬁned
as the time from surgery until the date of cancer-related death.
Survival rates for DFS and OS were estimated by the Kaplan–Meier
method. The survival comparisons between the different groupswere
carried out by the Log-rank test.
The secondary aim of this study was to identify predictors
for micrometastases in SLN. We subdivided patient and tumor-
related factors. Continuous variables were expressed as mean and
standard deviation (SD) or as median and range. The association
between micrometastases and patients and tumor-related factors
were analyzed by non-parametric test as appropriate.
Multivariate analysis was performed by stepwise backward logistic
regression, including only variables with p < 0.1 at univariate tests.
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Table 1
Patient and tumor characteristics
Characteristic Number (%) or Mean±SD
Age 61.1±12.4
Multifocalitya
Yes 217 (11.1)
No 1733 (88.9)
Tumor size (cm) 1.8±1.1
Histology
Ductal 1464 (74.1)
Lobular 213 (10.8)
Other 299 (15.1)
p T stagea
Tis 30 (1.5)
T1 1318 (67.3)
T2 522 (26.7)
T3 34 (1.7)
T4 53 (2.7)
p Na
N0 1308 (69.1)
Nmi 72 (3.8)
N1–3 513 (27.1)
Gradinga
G1 146 (8.1)
G2 1224 (67.5)
G3 443 (24.4)
Lymphovascular invasiona
Yes 130 (23.7)
No 419 (76.3)
ER%a 69.6±36.4
PgR%a 44.5±37.1
c-erb-B2a 12.8±27.2
Ki 67a 24.3±16.9
p53a 11.9±24.4
a Data not available for all patients.
The level of signiﬁcance was set, as usual, at p < 0.05 (two-tailed
model for unpaired data).
All statistical tests were two sided. Statistical analyses were
performed by SPSS v.13 software for Windows.
3. Results
From January 1998 to March 2011, 1,976 consecutive patients with
non-metastatic invasive breast cancer underwent surgical treatment.
Among them 1,080 underwent SLNB (54.6%), in 853 cases associated
with breast conservative surgery, and in 227 patients with radical
mastectomy. Patient and tumor characteristics are reported in
Table 1.
A mean number of 2.1±1.4 (range 1–13) SLN per patient was
collected for a total of 2,294 nodes. The SLNs were macrometastatic
in 181 patients (16.7%) and micrometastatic in 72 patients (3.3%).
Among the 253 patients with positive SLN, 237 (93.6%) underwent
complete ALND, adding to the 738 patients who underwent complete
ALND ab initio. Among the patients with positive SLNs, 16 did not
undergo complete ALND because of high surgical risk or patient’s
choice.
Up to December 2010, 46 patients died from breast cancer, and
actuarial OS at 12, 36 and 60 months was 99.8%, 98.7% and 97.0%
(Fig. 1).
Fig. 1. Actuarial overall survival up to 60 months.
Fig. 2. Actuarial disease-free survival up to 60 months.
During follow up 133 recurrences were observed: the actuarial DFS
at 12, 36 and 60 months was 99.2%, 95.7% and 92.0% (Fig. 2).
TheOS of the 72 patientswithmicrometastases in SLN at 60months
was 100%, similar to that of patients with negative SLN (98.7%).
Surprisingly, for the group of patients with micrometastases in SLN
the DFS at 60 months (95.7%) was also similar to that of patients
with negative SLN (94.6%), quite different from the DFS of N1–N3
patients (85.8%).
No statistically signiﬁcant difference in overall survival and disease-
free survival were detected between patients with negative SLN
and patients with SLN micrometastases. Statistically signiﬁcant
differences in OS and DFS were observed between patients with
N1mi and the group with N1–N3 sentinel node (p < 0.001 and
p=0.04) and also between patients with negative SLN and those with
macrometastatic SLN (p< 0.001 for both) (Figs.3, 4).
Table 2 reports the results of univariate analysis for predictors
of SLN micrometastases. The results of multivariate analysis are
displayed in Table 3. The presence of peritumoral lymphovascular in-
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Fig. 3. Overall survival (OS) comparison between negative SLN (N0), SLN micro-
metastases (N1mi) and SLN macrometastases (N1–N3).
Fig. 4. Disease-free survival (DFS) comparison between negative SLN (N0), SLN micro-
metastases (N1mi) and SLN macrometastases (N1–N3).
vasion represents the only independent predictor of micrometastases
in the SLN (Table 3).
In order to compare the prognostic role of micrometastases in SLN
and the peritumoral lymphovascular invasion (LI), and to understand
their cause–effect relation, we stratiﬁed the patients into 4 groups:
(1) patients with SLN micrometastases and LI;, (2) patients with SLN
micrometastases without LI, (3) patients without micrometastases
but with LI, and (4) patients without micrometastases andwithout LI,
andwe comparedOS andDFS by theKaplan–Meiermethod (Figs. 5, 6).
The peritumoral LI seems to have a greater prognostic role than the
presence of micrometastases in SLN in our cohort of patients.
4. Discussion
Sentinel lymph node biopsy determines with high accuracy the
axillary lymph nodes status and is one of the prognostic indicators
that inﬂuence the choice of local and systemic therapy in breast
cancer management. 9,18,19 It is currently known, however, that there
Table 2
Results of multivariate analysis of the predictors of SLN micrometastases
Characteristic Number/total or Mean±SD
SLN N1mi SLN N0
p-value
Age 60.5±11.4 60.6±12.1 0.755
Multifocalitya 0.026
Yes 12/71 116/1294
No 59/71 1178/1294
Tumor size (cm) 2.0±0.9 1.6±0.9 <0.001
Histology <0.001
Ductal 67/72 922/1306
Lobular 4/72 137/1306
Other 1/72 247/1306
p Ta 0.018
Tis 0/71 30/1306
T1 45/71 993/1306
T2 24/71 256/1306
T3 2/71 15/1306
T4 0/71 12/1306
Gradinga 0.043
G1 1/67 121/1212
G2 53/67 819/1212
G3 13/67 272/1212
Lymphovascular invasiona <0.001
Yes 14/35 44/360
No 21/35 316/360
ER%a 81.2±30.8 70.2±36.2 0.003
PgR%a 58.6±36.0 45.7±37.5 0.004
c-erb-B2a 8.8±19.3 11.4±25.6 0.215
Ki 67a 21.6±17.8 23.4±16.9 0.237
p53a 12.0±22.4 11.7±24.1 0.024
a Data not available for all patients.
Table 3
Results of regression model for multivariate analysis
Characteristic Odds ratio 95% CI P-value
Lymphovascular invasion
Yes 5.212 2.130–12.758 <0.001
No 1
Fig. 5. Overall survival (OS) comparison between four groups of patients: (1) green
line: patients with SLN micrometastases and LI; (2) yellow: patients with SLN
micrometastases without LI; (3) blue: patients without micrometastases but with LI,
and (4) purple: patients without micrometastases and without LI.
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Fig. 6. Disease-free survival (DFS) comparison between four groups of patients:
(1) green line: patients with SLNmicrometastases and LI; (2) yellow: patients with SLN
micrometastases without LI; (3) blue: patients without micrometastases but with LI,
and (4) purple: patients without micrometastases and without LI.
are other factorswhich inﬂuence the choice of administering adjuvant
therapies.
Since the introduction of the SLNB procedure into clinical prac-
tice, axillary lymph node micrometastases are more likely to be
detected. 18,20–25 This is because the pathologist can focus on a
few lymph nodes, which can be analyzed more thoroughly by step
sectioning and immunohistochemistry. 22 Conversely, the systematic
use of step sectioning and immunohistochemistry is not feasible
in the assessment of all nodes in ALND specimens because of
time and ﬁnancial constraints. 12 However, the detection rate of
micrometastases varies among different histopathological techniques
and protocols.
In our cohort of patients who underwent SLNB, 3.3%were classiﬁed
as N1mi with micrometastases only in the SLN. In the literature
the rate of micrometastase identiﬁcation in the SLN ranges between
2.3% and 27% 26; this large range stems from the different modalities
of SLN pathological examination, for which there is not yet an
international standardized procedure. Additionally, we retrieved few
micrometastases probably because we considered as cases only those
patients who had isolated micrometastases without any other lymph
nodes involved.
The prognostic signiﬁcance and therapeutic implications of SLN
micrometastases remain a matter of great debate. In our study
micrometastases in the SLN are not associated with worse prognosis
than that for N0 patients. Indeed, the OS andDFS differwith statistical
signiﬁcance from those of the N+ (N1–N3) group (Figs.3, 4).
During the ALND era, various retrospective studies reported a
signiﬁcant disease-free and overall survival disadvantage for breast
cancer patients with micrometastases; however, others failed to ﬁnd
any association. 15,27,28
The American Society of Clinical Oncology (ASCO) has published
a study regarding the different therapeutical approaches adopted
by ASCO members (surgeons, oncologists, radiotherapists) in case of
micrometastatic sentinel lymph nodes. 29 Adjuvant chemotherapy is
considered by most of the ASCO members as a treatment that cannot
be renounced in N1mi patients without unanimous consensus about
treatment modality. Only 23% of the specialists consulted perform
and recommend ADLN in N1mi patients; more often (73%) they
recommend ALND based on other prognostic tumor-related factors
such as tumor size, histological grade and peritumoral LI. 29,30
On the contrary, in recent studies the presence of micrometastatic
SLN is correlated with a prognosis lower than that for N0 pa-
tients. 28,31–33 Particularly Chen S et al. attribute to patients with
micrometastases in the SLN a prognosis intermediate between those
for N0 and N+ (N1–N3). 33,34
Our data support the consideration by Langer et al. who consider
the axillary recurrence risk in N1mi patients so slight as to consider
ADLN to be overtreatment. 15 The absence of a statistically signiﬁcant
difference between the prognoses for N0 and N1mi patients in our
study could justify the possibility to avoid complete ALND and,
additionally, to prevent a systemic adjuvant overtreatment in patients
with micrometastases in the SLN.
Our results indicate that the micrometastases in the SLN do not
signiﬁcantly affect the prognosis. In accordance with our results,
the IBCSG 23-01 phase 3 randomized controlled trial conﬁrms
that axillary dissection could be avoided in patients with limited
sentinel lymph node disease. 35 Trial IBCSG 23-01 was a two-
group, multicenter, randomized phase 3 trial comparing no axillary
dissection with axillary dissection in patients with breast cancer and
micrometastases in sentinel lymph node. In this study about half of
patients have no other axillary involvement and axillary dissection
can be considered an overtreatment for them.
Our achievements are consistent also with those of the ACOSOG
Z0011 trial, a phase 3 non-inferiority trial enrolling patients with
limited sentinel lymph node disease randomized to undergo ALND
or no further axillary treatment. 7 The American College of Surgeons
Oncology Group (ACOSOG) tested the hypothesis that complete
axillary lymph node dissectionmay not be necessary for womenwith
sentinel lymphnodemetastases and early breast cancer. ALNDdid not
signiﬁcantly inﬂuence overall or disease-free survival of patients
with clinical T1–2 breast cancer and a positive SLN, treated with
lumpectomy, radiotherapy and adjuvant systemic therapy. 7
The paper byWasif et al. 29 supported our ﬁndings and opens a new
scenario for changing clinical practice in the management of axilla in
early breast cancer patients. The use of axillary radiation including
level I and II axilla as an alternative to treat SLNB micrometastases
instead of ALND was an option often selected.
In fact, several studies have reported on the use of radiotherapy
instead of ALND for SLNB-positive nodes, although the data are
difﬁcult to interpret because of the use of systemic therapy and breast
tangential radiation. 36
Findings from the AMAROS study which compared ALND and
axillary radiotherapy in patients with metastatic SLN demonstrated
that axillary dissection had no inﬂuence on the choice of adjuvant
systemic treatment. 37,38 Accordingly, the information offered by
axillary dissection is no longer useful.
In our study we have identiﬁed no prognostic difference between
the N1mi and N0 groups, so we analyzed the patient- and tumor-
related factors associated with micrometastatic SLN.
Peritumoral LI emerged as the only independent predictive factor
for the presence of micrometastases in SLN and it affected patient
survival independently of micrometastases.
Even though our study is limited by its retrospective design and
some chronological bias for the long observational time interval, we
can conclude that SLN micrometastases could represent an epiphe-
nomenon of peritumoral LI which, if at all, impacts independently on
the survival of patients with invasive breast cancer.
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